Ken Kishida

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6211288/publications.pdf Version: 2024-02-01



KEN KISHIDA

#	Article	IF	CITATIONS
1	Correlation of insulin resistance and motor function in spinal and bulbar muscular atrophy. Journal of Neurology, 2017, 264, 839-847.	1.8	27
2	Visualized macrophage dynamics and significance of S100A8 in obese fat. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2058-66.	3.3	43
3	Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded androgen receptors. Human Molecular Genetics, 2015, 24, 314-329.	1.4	32
4	Adiponectin as a routine clinical biomarker. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 119-130.	2.2	147
5	High serum C1q-binding adiponectin levels in male patients with acute coronary syndrome. Cardiovascular Diabetology, 2014, 13, 9.	2.7	11
6	Accumulation of adiponectin in inflamed adipose tissues of obese mice. Metabolism: Clinical and Experimental, 2014, 63, 542-553.	1.5	26
7	Increased serum C1q-binding adiponectin complex to total-adiponectin ratio in men with multi-vessel coronary disease. Diabetology and Metabolic Syndrome, 2014, 6, 64.	1.2	2
8	Short-term intervention reduces bioelectrical impedance analysis-measured visceral fat in type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2014, 103, e27-e29.	1.1	4
9	Tracing the movement of adiponectin in a parabiosis model of wildâ€ŧype and adiponectinâ€knockout mice. FEBS Open Bio, 2014, 4, 276-282.	1.0	5
10	Clinical significance of visceral adiposity assessed by computed tomography: A Japanese perspective. World Journal of Radiology, 2014, 6, 409.	0.5	71
11	Serum C1q- binding adiponectin in maintenance hemodialysis patients. BMC Nephrology, 2013, 14, 50.	0.8	12
12	Effects of pitavastatin on HDL metabolism. Clinical Lipidology, 2013, 8, 55-68.	0.4	3
13	Molecular Mechanisms of Diabetes and Atherosclerosis: Role of Adiponectin. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2012, 12, 118-131.	0.6	59
14	Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study). Annals of Medicine, 2012, 44, 82-92.	1.5	156
15	Importance of Assessing the Effect of Statins on the Function of High- Density Lipoproteins on Coronary Plaque. Cardiovascular & Hematological Disorders Drug Targets, 2012, 12, 28-34.	0.2	11
16	Visceral adiposity as a target for the management of the metabolic syndrome. Annals of Medicine, 2012, 44, 233-241.	1.5	80
17	Reduction of Visceral Fat Correlates with the Decrease in the Number of Obesity-Related Cardiovascular Risk Factors in Japanese with Abdominal Obesity (VACATION-J Study). Journal of Atherosclerosis and Thrombosis, 2012, 19, 1006-1018.	0.9	39
18	Clinical Importance of Assessment of Type 2 Diabetes Mellitus with Visceral Obesity. A Japanese Perspective. Current Diabetes Reviews, 2012, 8, 84-91.	0.6	21

Ken Kishida

#	Article	IF	CITATIONS
19	Predictors of deterioration of glucose tolerance and effects of lifestyle intervention aimed at reducing visceral fat in normal glucose tolerance subjects with abdominal obesity. Journal of Diabetes Investigation, 2011, 2, 218-224.	1.1	4
20	Relationships between Circulating Adiponectin Levels and Fat Distribution in Obese Subjects. Journal of Atherosclerosis and Thrombosis, 2011, 18, 592-595.	0.9	58
21	Clinical significance of visceral fat reduction through health education in preventing atherosclerotic cardiovascular disease - Lesson from the Amagasaki Visceral Fat Study: A Japanese perspective. Nutrition and Metabolism, 2011, 8, 57.	1.3	13
22	Disturbed secretion of mutant adiponectin associated with the metabolic syndrome. Biochemical and Biophysical Research Communications, 2003, 306, 286-292.	1.0	66
23	Successful Use of 111In-Pentetrotide Scintigraphy for Localizing Ectopic Adrenocorticotropin-Producing Bronchial Carcinoid Tumor in a Patient with Cushing's Syndrome. Internal Medicine, 2003, 42, 996-1005.	0.3	7
24	The Expression of SPARC in Adipose Tissue and Its Increased Plasma Concentration in Patients with Coronary Artery Disease. Obesity, 2001, 9, 388-393.	4.0	45
25	Adipocyte-Derived Plasma Protein, Adiponectin, Suppresses Lipid Accumulation and Class A Scavenger Recentor Expression in Human Monocyte-Derived Macrophages, Circulation, 2001, 103, 1057-1063.	1.6	1,184